CD1C and cancer: Further studies are warranted to improve the DN4.99 TCR affinity for the mLPA–CD1c complex, or to pharmacologically sustain CD1c expression on malignant cells, in order to target cancer cells expressing low CD1c levels and prevent/minimize possible immune evasion.